Lassaad Chtourou

Prof. Lassaad Chtourou

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2023
Verified
Closed access
LCLassaad Chtourou
Lassaad Chtourou
MMManel Moalla
Manel Moalla
HGHela Gdoura
Hela Gdoura
HSHend Smaoui
Hend Smaoui
OKOns Khrouf
Ons Khrouf
NTNabil Tahri
Nabil Tahri

1 December 2013
Verified
Journal Article
Closed access
LML Mnif
L Mnif
MMM Medhioub
M Medhioub
MBM Boudabbous
M Boudabbous
LCLassaad Chtourou
Lassaad Chtourou
AAA Amouri
A Amouri
NTN Tahri
N Tahri

1 February 2012 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
LML. Mnif
L. Mnif
AGA. Grati
A. Grati
LCLassaad Chtourou
Lassaad Chtourou
MBM. Boudabbous
M. Boudabbous
AAA. Amouri
A. Amouri
NTN. Tahri
N. Tahri
L. Mnif, A. Grati, L. Chtourou, M. Boudabbous, A. Amouri, N. Tahri; P128 Intima media thickness of the common carotid artery is significantly higher in inflamm

23 November 2016 in Journal Africain d’Hépato-Gastroentérologie
Verified
Journal Article
Closed access
PDF file
LCLassaad Chtourou
Lassaad Chtourou
MBM. Boudabbous
M. Boudabbous
LML. Mnif
L. Mnif
FTF. Trabelsi
F. Trabelsi
AGA. Grati
A. Grati
NTN. Tahri
N. Tahri
Le syndrome de Plummer-Vinson (SPV), aussi appelé dysphagie sidéropénique, est une entité très rare qui associe une triade classique : l’anémie ferriprive, la dysphagie et le diaphragme œsophagien supérieur. Son association avec la maladie cœliaque a été rarement rapportée.

6 December 2017
Verified
Book Chapter
Open access
PDF file
MBMona Boudabous
Mona Boudabous
HGHéla Gdoura
Héla Gdoura
LMLeila Mnif
Leila Mnif
LCLassaad Chtourou
Lassaad Chtourou
AGAmal Grati
Amal Grati
NTNabil Tahri
Nabil Tahri
The proton-pump inhibitor (PPI) is an effective and widely used treatment but may cause side effects, especially for the elderly. Materials and methods: this is a cross-sectional study including 45 patients older than 65 years, followed at our outpatient and treated with PPIs for at least a year. The indication for PPI, the results of any endoscopy, and the quality of the tolerance of these molecules is specified by the data folder. During the consultation, we conducted an interrogation to an update of the history and medications to our patients and a type checking of the molecule, the dose, and the quality of the observance. Results: patients were divided into 32 women and 13 men with a mean age of 75 ± 7 years (65–92). The average length of PPI use was 6 ± 4 years (1–16) with a consumption of a double dose for at least 1 year in 28.8% of cases. The prescribed dose was higher than the recommended dose in at least 15.5% of cases. PPIs were well tolerated. One patient had presented a microscopic colitis, revealed by diarrhea regressed after discontinuation of PPIs. Conclusion: PPIs were prescribed in elderly subjects by gastroenterologists, in a university center, with a high dose and long. In our series, this treatment is well tolerated in the elderly.

16 January 2018 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
MBM Boudabous
M Boudabous
ASA Siala
A Siala
LCLassaad Chtourou
Lassaad Chtourou
LML Mnif
L Mnif
AAA Amouri
A Amouri
NTN Tahri
N Tahri
The diagnosis of inflammatory bowel disease (IBD) at age over 60 years is between 10 and 15% of all IBD. This frequency is increasing due to the ageing of the population however, this group of elderly patients remains little studied and excluded from clinical trials. This was a retrospective study that included patients with IBD in the gastroenterology department between January 1, 2007 and December 31, 2015. The patients included were divided into two groups: group A patients in whom the diagnosis of IBD was made at an age greater than or equal to 60 years and group B including the subjects in whom the diagnosis of IBD was made at a younger age. A total of 305 subjects were included in the study, 30 of whom were over 60 years of age at the time of diagnosis of IBD, counting for a frequency of 9.8%. Among the elderly, 53.5% were between 60 and 70 years of age. Male predominance was noted in elderly subjects with a statistically significant difference from younger subjects (70% vs. 48%, p = 0.02). The elderly group had more patients with UC with a significant difference (73.3% vs. 58.2%, p = 0.008). The comparative analysis found no statistically significant differences in the extent of UC, the location and phenotype of Crohn’s disease between the two groups. In the elderly, subocclusive syndromes (0% vs. 13.5%, p = 0.03) and abdominal pain (26.7% vs. 49.1%, p = 0.02) were found less frequently. On the other hand, in elderly subjects, hypokalaemia was more frequently noted with a significant difference (23.3% vs. 9.1%, p = 0.025). Compared with younger subjects, elderly patients had fewer flares (0.11 vs. 0.21, p = 0.048) and fewer hospitalisations (1.53 vs.. 2.18, p = 0.034). We did not find any significant difference in the comparative analysis between the two groups regarding mortality and duration of follow-up. We found significantly more adverse effects on salicylates in the elderly (26.7% vs. 10.5%, p = 0.017). There was no significant difference in the frequency of surgery between the two groups. Our study found a high incidence of male and UC in IBD starting after the age of 60 with a more frequently atypical initial clinical presentation and fewer abdominal pain and subocclusive syndromes than younger subjects. The high frequency of comorbidities and hypokalaemia in elderly patients implies greater caution in the management of these patients. Although we were able to demonstrate a low incidence of severe relapses / year and a lower use of corticosteroids in the elderly relative to the young subject, adverse effects to salicylates were more frequent in these patients, which requires closer surveillance from the prescribers.